L-Asparaginase-induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children

Neuropediatrics

Volumn 39, Issue 1, 2008, Pages 46-50

  Hourani, R ^a   Abboud, M ^a   Hourani, M ^a   Khalifeh, H ^b   Muwakkit, S ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b RAFIC HARIRI UNIVERSITY HOSPITAL   (Lebanon)

Author keywords

L Asparaginase; Leukemia; MRI; Neurotoxicity; PRES

Indexed keywords

ASPARAGINASE; DEXAMETHASONE; METHOTREXATE; PHENYTOIN; PREDNISONE; VALPROIC ACID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BRAIN DISEASE; CASE REPORT; DRUG MEGADOSE; FEMALE; HUMAN; INTRACTABLE EPILEPSY; KARYOTYPE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHLEBOGRAPHY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; SCHOOL CHILD; SEPTIC SHOCK; TETRAPLOIDY;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ASPARAGINASE; BRAIN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SEIZURES; SHOCK, SEPTIC;

EID: 45149132242     PISSN: 0174304X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1076740     Document Type: Article

References (35)

1. Antunes NL. Seizures in children with systemic cancer. Pediatr Neurol 2003; 28: 190-193
2. Bartynski WS, Boardman JF, Zeigler ZR, Shadduck RK, Lister J. Posterior reversible encephalopathy syndrome in infection, sepsis, and shock. AJNR Am J Neuroradiol 2006; 27: 2179-2190
3. Bartynski WS, Zeigler Z, Spearman MP, Lin L, Shadduck RK, Lister J. Etiology of cortical and white matter lesions in cyclosporin-A and FK-506 neurotoxicity. AJNR Am J Neuroradiol 2001; 22: 1901-1914
4. Bushara KO, Rust RS. Reversible MRI lesions due to pegaspargase treatment of non-Hodgkin's lymphoma. Pediatr Neurol 1997; 17: 185-187
5. Chaturvedi S, Ansell J, Recht L. Should cerebral ischemic events in cancer patients be considered a manifestation of hypercoagulability? Stroke 1994; 25: 1215-1218
6. Chen CY, Zimmerman RA, Faro S, Bilaniuk LT, Chou TY, Molloy PT. Childhood leukemia: central nervous system abnormalities during and after treatment. AJNR Am J Neuroradiol 1996; 17: 295-310
7. Chou MC, Lai PH, Yeh LR et al. Posterior reversible encephalopathy syndrome: magnetic resonance imaging and diffusion-weighted imaging in 12 cases. Kaohsiung J Med Sci 2004; 20: 381-388
8. Delanty N, Vaughan C, Frucht S, Stubgen P. Erythropoietin- associated hypertensive posterior leukoencephalopathy. Neurology 1997; 49: 686-689
9. Duru F, Ertem U, Dagdemir A et al. Coexistence of life threatening chemotherapy related leukoencephalopathy, saggital sinus thrombosis and multiple organ failure in a child with acute lymphoblastic leukemia: an unusual case with clinical recovery. Leuk Lymphoma 1997; 26: 377-385
10. Ferraz-Filho JR, Rocha-Filho JA, Bichuette TF, Albuquerque RC de, Sanchez RA, Souza AS. Studying the evolution and the magnetic resonance findings of reversible posterior leukoencephalopathy in children. Arq Neuropsiquiatr 2006; 64: 718-722
11. Fleischhack G, Solymosi L, Reiter A, Bender-Gotze C, Eberl W, Bode U. Imaging methods in diagnosis of cerebrovascular complications with L-asparaginase therapy. Klin Padiatr 1994; 206: 334-341
12. Gugliotta L, Mazzucconi MG, Leone G et al. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group. Eur J Haematol 1992; 49: 63-66
13. Hinchey J, Chaves C, Appignani B et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334: 494-500
14. Ho Y, Arahata Y, Goto Y et al. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol 1998; 19: 415-417
15. Kieslich M, Porto L, Lanfermann H, Jacobi G, Schwabe D, Bohles H. Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2003; 25: 484-487
16. Kinoshita T, Moritani T, Shrier DA et al. Diffusion-weighted MR imaging of posterior reversible leukoencephalopathy syndrome: a pictorial essay. Clin Imaging 2003; 27: 307-315
17. Larson RA, Fretzin MH, Dodge RK, Schiffer CA. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia 1998; 12: 660-665
18. Lee JH, Kim SW, Sung Kim J. Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature. Clin Neurol Neurosurg 2000; 102: 33-36
19. Morris EB, Laningham FH, Sandlund JT, Khan RB. Posterior reversible encephalopathy syndrome in children with cancer. Pediatr Blood Cancer 2007; 48: 152-159
20. Nakasu Y, Nakasu S, Morikawa S, Uemura S, Inubushi T, Handa J. Diffusion-weighted MR in experimental sustained seizures elicited with kainic acid. AJNR Am J Neuroradiol 1995; 16: 1185-1192
21. Narbone MC, Musolino R, Granata F, Mazzu I, Abbate M, Ferlazzo E. PRES: posterior or potentially reversible encephalopathy syndrome? Neurol Sci 2006; 27: 187-189
22. Nomura K, Ohno R, Hamaguchi K, Hata T, Hatanaka H, Matsuyama H. Clinicopathological report of cisplatin encephalopathy. Rinsho Shinkeigaku 1995; 35: 64-69
23. Norman JK, Parke JT, Wilson DA, MacNall-Knapp RY. Reversible posterior leukoencephalopathy syndrome in children undergoing induction therapy for acute lymphoblastic leukemia. Pediatr Blood Cancer 2007; 49: 198-203
24. Nowak-Gottl U, Kuhn N, Wolff JE et al. Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase-treated children. Eur J Haematol 1996; 56: 35-38
25. Ohnuma T, Holland JF, Freeman A, Sinks LF. Biochemical and pharmacological studies with asparaginase in man. Cancer Res 1970; 30: 2297-2305
26. Osborn A, Blaser S, Salzman K. Diagnostic Imaging: Brain first edn. Saunders, Philadelphia 2004
27. Rangi PS, Partridge WJ, Newlands ES, Waldman AD. Posterior reversible encephalopathy syndrome: a possible late interaction between cytotoxic agents and general anaesthesia. Neuroradiology 2005; 47: 586-590
28. Rathi B, Azad RK, Vasudha N, Hissaria P, Sawlani V, Gupta RK. L-Asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia. Pediatr Neurosurg 2002; 37: 203-205
29. Rogers LR. Cerebrovascular complications in cancer patients. Neurol Clin 2003; 21: 167-192
30. Sanchez-Carpintero R, Narbona J, Lopez de Mesa R, Arbizu J, Sierrasesumaga L. Transient posterior encephalopathy induced by chemotherapy in children. Pediatr Neurol 2001; 24: 145-148
31. Schwartz RB, Bravo SM, Klufas RA et al. Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. AJR Am J Roentgenol 1995; 165: 627-631
32. Shin RK, Stern JW, Janss AJ, Hunter JV, Liu GT. Reversible posterior leukoencephalopathy during the treatment of acute lymphoblastic leukemia. Neurology 2001; 56: 388-391
33. Sibai BM. Eclampsia. VI. Maternal-perinatal outcome in 254 consecutive cases. Am J Obstet Gynecol 1990; 163: 1049-1054; discussion 1054-1055
34. Suminoe A, Matsuzaki A, Kira R et al. Reversible posterior leukoencephalopathy syndrome in children with cancers. J Pediatr Hematol Oncol 2003; 25: 236-239
35. Vaughn DJ, Jarvik JG, Hackney D, Peters S, Stadtmauer EA. High-dose cytarabine neurotoxicity: MR findings during the acute phase. AJNR Am J Neuroradiol 1993; 14: 1014-1016